Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>HSBC Research Expects JD HEALTH (06618.HK) to Maintain Strong Rev. Growth This Yr, Lifts TP to $80
Recommend 7 Positive 6 Negative 3 |
||||
|
||||
|
JD HEALTH (06618.HK) announced its annual results yesterday, with quarterly results standing out, further proving that its strategy focusing on strengthening supply chain capabilities and user stickiness can continue to yield positive results, HSBC Global Research published a research report saying. The Group's competitive advantage solidified its user base's perception of JD HEALTH and further strengthened its partnerships with pharmaceutical companies, creating a virtuous cycle. Supported by continuous growth in prescription drugs, HSBC Global Research was confident that JD HEALTH's robust revenue growth can be sustained, and raised its 2026/ 2027 revenue forecasts by 1%. After rolling over its discounted cash flow valuation by one year and adjusting its foreign exchange forecasts and beta, the broker lifted its target price from $77.5 to $80, with rating kept at Buy. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
